Compounds > gentamicin
Page last updated: 2024-10-27

gentamicin and Leishmaniasis, Cutaneous

gentamicin has been researched along with Leishmaniasis, Cutaneous in 14 studies

Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.

Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.

Research Excerpts

ExcerptRelevanceReference
"Paromomycin-based topical treatments were shown to be effective in curing cutaneous leishmaniasis (CL) lesions caused by Leishmania major in Tunisia."2.90Topical paromomycin for New World cutaneous leishmaniasis. ( Adams, RC; Grogl, M; Jiménez, AI; Kreishman-Detrick, M; Lawrence, K; McCarthy, WF; Norwood, JA; Pascale, JM; Ransom, J; Scott, C; Sosa, N; Tang, D; Weina, PJ, 2019)
" Pharmacokinetic parameters for gentamicin could not be calculated because detectable levels were rarely evident."2.78Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. ( Grogl, M; Kopydlowski, KM; Kreishman-Deitrick, M; Lin, YJ; Llanos-Cuentas, A; Nielsen, C; Ransom, JH; Ravis, WR; Smith, KS; Smith, PL; Sosa, N, 2013)
"Although cutaneous leishmaniasis is seen only rarely in the United States, it should be considered when diagnosing new skin lesions after travel to affected countries."2.58Cutaneous Leishmaniasis in an American Adolescent Returning From Israel. ( Ganjaei, KG; Gaur, S; Lawton, K, 2018)
"Cutaneous leishmaniasis is presently treated with 20 days of parenteral therapy with a frequently toxic drug (antimony)."1.30Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. ( Berman, JD; Ellis, WY; Grogl, M; Schuster, BG, 1999)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's4 (28.57)29.6817
2010's8 (57.14)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Mouri, O1
Melenotte, C1
Guéry, R1
Cotteret, C1
Schweitzer-Chaput, A1
Perignon, A1
Thellier, M1
Bourrat, E1
Kaguelidou, F1
Siriez, JY1
Malvy, D1
Gangneux, JP1
Duvignaud, A1
Ravel, C1
Cisternino, S1
Ransom, J4
Caumes, E1
Lortholary, O1
Grogl, M8
Buffet, P2
Ganjaei, KG1
Lawton, K1
Gaur, S1
Sosa, N4
Pascale, JM1
Jiménez, AI1
Norwood, JA2
Kreishman-Detrick, M1
Weina, PJ1
Lawrence, K1
McCarthy, WF3
Adams, RC2
Scott, C2
Tang, D2
Capitán, Z1
Nieto, J1
Nieto, M1
Calzada, J1
Paz, H1
Spadafora, C1
Kreishman-Deitrick, M4
Kopydlowski, K1
Ullman, D1
Berman, J2
Ravis, WR1
Llanos-Cuentas, A1
Kopydlowski, KM2
Nielsen, C1
Smith, KS2
Smith, PL3
Ransom, JH1
Lin, YJ1
Monge-Maillo, B1
López-Vélez, R1
Ben Salah, A2
Buffet, PA1
Morizot, G2
Ben Massoud, N1
Zâatour, A2
Ben Alaya, N2
Haj Hamida, NB1
El Ahmadi, Z2
Downs, MT1
Dellagi, K1
Daneshvar, H2
Burchmore, R1
Hagan, P2
Phillips, RS2
Costa, Sdos S1
de Assis Golim, M1
Rossi-Bergmann, B1
Costa, FT1
Giorgio, S1
Ben Messaoud, N1
Guedri, E1
Bettaieb, J1
Gharbi, A1
Belhadj Hamida, N1
Boukthir, A1
Chlif, S1
Abdelhamid, K1
Louzir, H1
Mokni, M1
Nielsen, CJ1
Ullman, DR1
Thorne, GD1
Rice, RM1
Magill, AJ1
Coombs, GH1
Asilian, A1
Faghihi, G1
Siadat, AH1
Hejazi, H1
Shahtalebi, M1
Sadeghian, G1
Mostaghim, M1
Radan, MR1
Schuster, BG1
Ellis, WY1
Berman, JD1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama[NCT01083576]Phase 230 participants (Actual)Interventional2010-03-31Completed
Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru[NCT01032382]Phase 230 participants (Actual)Interventional2010-01-31Completed
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: a Phase 2 Study in the Old World[NCT00703924]Phase 292 participants (Actual)Interventional2003-03-31Completed
A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)[NCT00606580]Phase 3375 participants (Actual)Interventional2008-01-31Completed
Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study[NCT03096457]Phase 2/Phase 380 participants (Actual)Interventional2017-04-15Completed
Paromomycin Topical Cream Treatment Protocol for Individuals With Uncomplicated Cutaneous Leishmaniasis[NCT01641796]0 participants Expanded AccessNo longer available
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions

Final cure as defined by the primary outcome measure AND and cure of all other lesions by Day 168. (100% re-epithelialization of all ulcerated lesions and resolution of all other type of lesions) (NCT01083576)
Timeframe: 168 days

InterventionParticipants (Number)
Paromomycin Alone Treatment8
WR 279,39613

Number of Participants Who Obtained Final Clinical Cure of Index Lesion

Number of participants who had initial clinical cure (100% re-epithelialization of index lesion by Day 63) OR initial clinical improvements (> 50% re-epithelialization of index lesion followed by Day 63 by 100% re-epithelialization of the index lesion on or before Day 100), AND no relapse of index lesion. (NCT01083576)
Timeframe: 168 days

InterventionParticipants (Number)
Paromomycin Alone Treatment9
WR 279,39613

Detectable Paromomycin or Gentamicin Plasma Levels

Proportion of subjects with any detectable Paromomycin or Gentamicin plasma levels on a study day when blood for PK was collected (NCT01083576)
Timeframe: 20 days

,
InterventionParticipants (Number)
Any detectable gentamicinAny detectable paromomycin
Paromomycin Alone Treatment08
WR 279,39618

Paromomycin Plasma Concentrations in Adults

Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults (NCT01083576)
Timeframe: Day 4 to Day 28

,
Interventionng/mL (Mean)
Day 4Day 7Day 12Day 17Day 20Day 28
Paromomycin Alone Treatment013.16.644.054.60
WR 279,39617.817.626.426.331.40

Paromomycin Plasma Concentrations in Children

Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children (NCT01083576)
Timeframe: Days 1 and 20

,
Interventionng/mL (Mean)
Study Day 1Study Day 20
Paromomycin Alone Treatment116.3992.7
WR 279,39698.6634.2

Pharmacokinetic Parameter: Area Under the Curve (AUC)

Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng*hr/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment15715603
WR 279,396863.44740

Pharmacokinetic Parameter: AUC/D

Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: Days 1 and 20

,
Interventionhr/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment715.21725
WR 279,396345.91380

Pharmacokinetic Parameter: Cmax

Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment219.0751.0
WR 279,396121561.0

Pharmacokinetic Parameter: Cmax/D

Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Intervention1/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment104.0227
WR 279,39661.3179

Pharmacokinetic Parameter: t(1/2)

t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment7.035.3
WR 279,3964.07.0

Pharmacokinetic Parameter: Tmax

Tmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01083576)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment2.72.2
WR 279,3962.82.2

Serum Creatinine Levels

Blood creatinine was measured to assess possible nephrotoxicity associated with aminoglycosides (NCT01083576)
Timeframe: Day 1 and Day 20

,
Interventionmg/dL (Mean)
Study Day 1Study Day 20
Paromomycin Alone Treatment0.830.77
WR 279,3960.790.76

Final Clinical Cure for Index Lesions

"Final clinical cure was defined as follows:~Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,~Subject has initial clinical improvement (> 50% re-epithelialization of index lesion by nominal Day 63 followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,~Subject has no relapse of index lesion by Day 168. Relapse was defined as an index lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (> 0 x 0 mm measurement) by nominal day 168, or an index lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168." (NCT01032382)
Timeframe: Initial clinical cure by day 63 and no relapse by day 168

Interventionparticipants (Number)
Paromomycin Alone Treatment11
WR 279,3969

Final Clinical Cure on All Lesions Independent of Subjects

"Final clinical cure was defined as follows:~Subject has initial clinical cure (100% re-epithelialization of lesion by nominal Day 63); OR,~Subject has initial clinical improvement (> 50% re-epithelialization of lesion by nominal Day 63 followed by 100% re-epithelialization of the lesion on or before nominal Day 100; AND,~Subject has no relapse of lesion by Day 168. Relapse was defined as a lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (> 0 x 0 mm measurement) by nominal day 168, or a lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168." (NCT01032382)
Timeframe: Initial clinical cure by day 63 and no relapse by day 168

InterventionCured ulcerated lesions (Number)
Paromomycin Alone Treatment12
WR 279,39614

Detectable Paromomycin Plasma Levels

Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults (NCT01032382)
Timeframe: Day 4, 7, 12, 17, 20, 28

,
Interventionng/mL (Mean)
Day 4Day 7Day 12Day 17Day 20Day 28
Paromomycin Alone Treatment12.110.336.2210.087.30
WR 279,39637.317.978.9162.0128.00

Number of Index Lesions Meeting Criteria for Clinical Cure During the Study

Number of study participants who meet the criteria for clinical cure (100% re-epithelialization) at specified timepoints during the study. (NCT01032382)
Timeframe: Day 1, 4, 7, 12, 17, 20, 28, 35, 42, 49, 56, 63, 100, 168

,
InterventionLesions meeting clinical cure criteria (Number)
Day 1Day 4Day 7Day 12Day 17Day 20Day 28Day 35Day 42Day 49Day 56Day 63Day 100Day 168
Paromomycin Alone Treatment00000158101011111211
WR 279,39600000061111121010109

Paromomycin Plasma Concentrations in Children

Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children (NCT01032382)
Timeframe: 0 and 4 hours on days 1 and 20

,
Interventionng/mL (Mean)
Day 1 hour 0Day 1 hour 4Day 20 hour 0Day 20 hour 4
Paromomycin Alone Treatment6.271.293.8744.0
WR 279,39622.1322.089.21030.0

Pharmacokinetic Parameter: Area Under the Curve (AUC)

Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng*hr/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment315413331
WR 279,39612288955

Pharmacokinetic Parameter: AUC/D

Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: Days 1 and 20

,
Interventionhr/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment996.73335
WR 279,396340.53155

Pharmacokinetic Parameter: Cmax

Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionng/mL (Mean)
Day 1Day 20
Paromomycin Alone Treatment5111400
WR 279,396155.0882

Pharmacokinetic Parameter: Cmax/D

Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Intervention1/ML (Mean)
Day 1Day 20
Paromomycin Alone Treatment185368
WR 279,39645.9283

Pharmacokinetic Parameter: t(1/2)

t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment2.557.17
WR 279,3964.516.81

Pharmacokinetic Parameter: Tmax

Pharmacokinetic Parameter: Tmax (NCT01032382)
Timeframe: 0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20

,
Interventionhr (Mean)
Day 1Day 20
Paromomycin Alone Treatment2.254.6
WR 279,39633

Rate of Relapse

"Relapse is defined as enlargement of the index lesion compared to previous measurement at any time after day 50 (+ 7 days) or not demonstrating CCR by study day 180. CCR was compared using uncorrected Fisher's exact test.~Confidence intervals (95%) were constructed on the difference between the two group proportions. The log-rank test was used to compare the time to complete re-epithelialization of the index lesion without relapse. Cure of all subjects lesions was also compared using the Fisher's exact test. To adjust for baseline differences in the treatment groups, a linear model for the proportion of subjects achieving CCR was fit for each baseline variable of interest with covariates for treatment group and the baseline variable." (NCT00703924)
Timeframe: 180 days

InterventionParticipants (Count of Participants)
WR 279,3960
Placebo3

Safety of WR 279,396 (AEs and SAEs)

Safety was evaluated on each day during daily administration of the topical products. Subjects were observed and questioned for the occurrence of solicited local side effects (eg, pain, erythema, edema) and solicited systemic side effects (eg, vertigo, tinnitus, diminished hearing). Non-solicited AE evaluations included spontaneous reports from subjects and clinical observations. (NCT00703924)
Timeframe: 180 days

,
InterventionAdverse Events (Number)
Solicated AEs- MildSolicited AEs- ModerateSolicited AEs- SevereNon-Solicited AEs- MildNon-Solicited AEs- ModerateNon-Soliciated AEs- SevereSAEs
Placebo4052201000
WR 279,39649112131001

Time to Complete Re-epithelialization of the Index Lesion Ulcer Without Relapse

100% re-epithelialization of the index lesion without having had a relapse. The log-rank test was used to compare the time to complete re-epithelialization. (NCT00703924)
Timeframe: 180 days

,,,
InterventionParticipants (Count of Participants)
WR 279,396Placebo
Day 10049
Day 180 (+7 Days)11
Day 201020
Day 503410

Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 42

(NCT00606580)
Timeframe: Days 42

InterventionPercentage of lesions (Number)
WR 279,396 Topical Treament51.7
Paromomycin Alone Topical Treatment81.6
Vehicle Placebo Cream58.1

Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 49

(NCT00606580)
Timeframe: Days 49

Interventionpercentage of lesions (Number)
WR 279,396 Topical Treament81.4
Paromomycin Alone Topical Treatment90.4
Vehicle Placebo Cream64.9

Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 98

(NCT00606580)
Timeframe: Days 98

Interventionpercentage of lesions (Number)
WR 279,396 Topical Treament91.5
Paromomycin Alone Topical Treatment98.9
Vehicle Placebo Cream92.2

Estimated Percentage Subjects With Re-epithelialization of the Index Lesion Without Relapse

For the first of the above analyses, subjects were considered to have endpoint events at the first assessment on or before Day 42 where complete re-epithelialization occurred at the index lesion that was not followed by a later assessment where ulceration was present. Subjects who did not have complete re-epithelialization by Day 42 or who relapsed after Day 42 were censored in the analysis at the Day 42 assessment. This analysis was only to be conducted through Day 42. (NCT00606580)
Timeframe: Day 42

Interventionpercentage of participants (Number)
WR 279,396 Topical Treament67.2
Paromomycin Alone Topical Treatment68.8
Vehicle Placebo Cream48.8

Final Clinical Cure Rate

"Final clinical cure was defined as an index lesion that met the criteria for initial clinical cure without relapse. Definitions for index lesion outcomes were as follows:~Initial Clinical Improvement: At least 50% to 99% reduction in the size of the measured lesion from the baseline measurement by the Day 42 evaluation.~Initial Clinical Cure: 100% re-epithelialization (ie, a 0 x 0 length x width measurement) of the lesion at the nominal Day 42 evaluation, or initial clinical improvement followed by 100% re-epithelialization by Day 98.~Relapse: Initial clinical cure followed by re-ulceration by Day 168, or initial clinical improvement followed by lesion enlargement by Day 168.~Final Clinical Cure: Initial clinical cure without relapse through study Day 168.Clinical Failure: Lack of at least initial clinical improvement by Day 42, or relapse." (NCT00606580)
Timeframe: Day 42, 98, and 168

Interventionparticipants (Number)
WR 279,396 Topical Treament101
Paromomycin Alone Topical Treatment102
Vehicle Placebo Cream73

Final Clinical Cure Rate (Per Protocol Dataset)

Final clinical cure was defined as an index lesion that met the criteria for initial clinical cure without relapse. Definitions for index lesion outcomes as described in the primary outcome measure. (NCT00606580)
Timeframe: Day 42, 98, and 168

Interventionparticipants (Number)
WR 279,396 Topical Treament101
Paromomycin Alone Topical Treatment102
Vehicle Placebo Cream73

Number of All Ulcerated Lesions Achieving 100% Re-epithelialization by Day 42

(NCT00606580)
Timeframe: Day 42

InterventionUlcerated lesions (Number)
WR 279,396 Topical Treament190
Paromomycin Alone Topical Treatment218
Vehicle Placebo Cream160

Number of Subjects Achieving Initial Clinical Improvement of the Index Lesion

(NCT00606580)
Timeframe: Day 42

Interventionparticipants (Number)
WR 279,396 Topical Treament105
Paromomycin Alone Topical Treatment107
Vehicle Placebo Cream77

Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions Without Subsequent Relapse

Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions at Day 42 without Subsequent Relapse from Day 42 Onward, (NCT00606580)
Timeframe: Day 168

Interventionparticipants (Number)
WR 279,396 Topical Treament83
Paromomycin Alone Topical Treatment84
Vehicle Placebo Cream60

Number of Subjects Achieving Re-epithelialization of the Index Lesion Without Relapse

Number of Subjects Achieving Re-epithelialization of the Index Lesion by Day 42 without Relapse from Day 42 Onward, Imputing Relapse for any Subject with a Missing Visit after Day 42 (NCT00606580)
Timeframe: Day 168

Interventionparticipants (Number)
WR 279,396 Topical Treament84
Paromomycin Alone Topical Treatment84
Vehicle Placebo Cream62

Number of Subjects With a Relapse on or After Day 42

(NCT00606580)
Timeframe: Day 168

Interventionparticipants (Number)
WR 279,396 Topical Treament4
Paromomycin Alone Topical Treatment3
Vehicle Placebo Cream2

Estimated Percentage of Subjects With Re-epithelialization of the Index Lesion Without Relapse at Various Times of Follow-up

(NCT00606580)
Timeframe: Days 42, 49, and 98

,,
Interventionpercentage of participants (Number)
Day 42Day 49Day 98
Paromomycin Alone Topical Treatment68.581.599.2
Vehicle Placebo Cream49.457.190.9
WR 279,396 Topical Treament67.272.994.3

Reviews

1 review available for gentamicin and Leishmaniasis, Cutaneous

ArticleYear
Cutaneous Leishmaniasis in an American Adolescent Returning From Israel.
    Journal of the Pediatric Infectious Diseases Society, 2018, Aug-17, Volume: 7, Issue:3

    Topics: Adolescent; Antiprotozoal Agents; Biopsy; Cellulitis; Diagnostic Errors; Female; Gentamicins; Humans

2018

Trials

6 trials available for gentamicin and Leishmaniasis, Cutaneous

ArticleYear
Topical paromomycin for New World cutaneous leishmaniasis.
    PLoS neglected tropical diseases, 2019, Volume: 13, Issue:5

    Topics: Administration, Topical; Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Dru

2019
Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.
    The American journal of tropical medicine and hygiene, 2013, Volume: 89, Issue:3

    Topics: Administration, Cutaneous; Adolescent; Child; Child, Preschool; Double-Blind Method; Drug Therapy, C

2013
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:10

    Topics: Adult; Child; Female; Gentamicins; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin

2013
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:10

    Topics: Adult; Child; Female; Gentamicins; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin

2013
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:10

    Topics: Adult; Child; Female; Gentamicins; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin

2013
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:10

    Topics: Adult; Child; Female; Gentamicins; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin

2013
WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.
    PLoS neglected tropical diseases, 2009, Volume: 3, Issue:5

    Topics: Adolescent; Adult; Aged; Aminoglycosides; Child; Child, Preschool; Double-Blind Method; France; Gent

2009
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Therapy, Combination

2013
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Therapy, Combination

2013
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Therapy, Combination

2013
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
    The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Therapy, Combination

2013
Efficacy of paromomicin and gentamicin patches in the treatment of cutaneous leishmaniasis.
    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2006, Volume: 12, Issue:6

    Topics: Adhesives; Administration, Cutaneous; Bandages; Drug Therapy, Combination; Gentamicins; Humans; Iran

2006

Other Studies

7 other studies available for gentamicin and Leishmaniasis, Cutaneous

ArticleYear
Self-application of aminoglycoside-based creams to treat cutaneous leishmaniasis in travelers.
    PLoS neglected tropical diseases, 2023, Volume: 17, Issue:8

    Topics: Aminoglycosides; Anti-Bacterial Agents; Antiprotozoal Agents; Gentamicins; Humans; Leishmaniasis, Cu

2023
Topical paromomycin and gentamicin for new world cutaneous leishmaniasis in Panama.
    The American journal of tropical medicine and hygiene, 2014, Volume: 90, Issue:6

    Topics: Female; Gentamicins; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin

2014
In response.
    The American journal of tropical medicine and hygiene, 2014, Volume: 90, Issue:6

    Topics: Female; Gentamicins; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin

2014
Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major.
    Parasitology, 2009, Volume: 136, Issue:11

    Topics: Animals; Antibodies, Protozoan; CD4-Positive T-Lymphocytes; Cells, Cultured; Female; Gentamicins; Hu

2009
Use of in vivo and in vitro systems to select Leishmania amazonensis expressing green fluorescent protein.
    The Korean journal of parasitology, 2011, Volume: 49, Issue:4

    Topics: Amebicides; Animals; Flow Cytometry; Gentamicins; Green Fluorescent Proteins; Host-Parasite Interact

2011
Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines.
    The Journal of infectious diseases, 2003, May-15, Volume: 187, Issue:10

    Topics: Animals; Bone Marrow Cells; Culture Media; Female; Gentamicins; Leishmania donovani; Leishmania infa

2003
Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    The Journal of parasitology, 1999, Volume: 85, Issue:2

    Topics: Administration, Topical; Animals; Antiprotozoal Agents; Benzethonium; Cricetinae; Drug Therapy, Comb

1999